All In Biotech

Drug Trial Radar · NCT05552469

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

A Phase 1b, Open Label, Multi-center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients With Myeloid Diseases

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

71

Actual

Start

May 8, 2023

Primary completion

Feb 1, 2027

Study completion Feb 1, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study CDFV890G12101 is an open-label, phase 1b, multicenter study with a randomized two-dose optimization part, and a dose expansion part consisting of three groups evaluating DFV890 in patients with myeloid diseases. The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, efficacy and recommended dose for single agent DFV890 in patients with lower risk (LR: very low, low or intermediate risk) myelodysplastic syndromes (LR MDS), lower risk chronic myelomonocytic leukemia (LR CMML) and High-Risk Clonal Cytopenia of Undetermined Significance (HR CCUS).

Conditions

  • Myeloid Diseases

Interventions

  • DFV890Drug

    DFV890 Single Agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose-limiting Toxicities (DLTs)Time frame: 28 days
  2. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 36 months
  3. Incidence of dose interruptions, discontinuations and reductionsTime frame: 36 months

Locations

25 sites in 8 countries. Site status is shown where the registry gives one.

  • Stanford Cancer Center

    Stanford, California

  • H Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • Northwestern University

    Chicago, Illinois

  • Sidney Kimmel CCC At JH

    Baltimore, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Weill Cornell Medicine NY-Presb

    New York, New York

  • Memorial Sloan Kettering Cancer Ctr

    New York, New York

  • Vanderbilt University Medical Ctr

    Nashville, Tennessee

  • Univ of TX MD Anderson Cancer Cntr

    Houston, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Novartis Investigative Site

    Grenoble, France

  • Novartis Investigative Site

    Nantes, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Lübeck, Germany

  • Novartis Investigative Site

    Dresden, Saxony, Germany

  • Novartis Investigative Site

    Leipzig, Saxony, Germany

  • Novartis Investigative Site

    Hong Kong, Hong Kong

  • Novartis Investigative Site

    Brescia, BS, Italy

  • Novartis Investigative Site

    Rozzano, MI, Italy

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Cardiff, United Kingdom

  • Novartis Investigative Site

    London, United Kingdom

  • Novartis Investigative Site

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.